Cancer Metabolism Company Metabomed Completes $18 Million Series A Financing

Israeli cancer metabolism company Metabomed LTD. announced today that it has completed an extension of its Series A round from current and new investors bringing the total of its raise to $ 18 million. Existing investors include MS Ventures, Boehringer Ingelheim Venture Fund (BIVF), Pontifax Fund, and the Technion Research and Development Foundation.

Press Release

back to overview